帕洛诺司琼联合不同疗程地塞米松在乳腺癌EC方案化疗中止吐效果的观察

摘要

目的:探讨帕洛诺司琼联合不同疗程的地塞米松在EC方案化疗中对于急性期呕吐及延迟期呕吐的止吐效果,为临床治疗提供一定参考.方法:纳入符合条件的乳腺癌术后首次EC方案化疗的患者80例,分为两组,均给予帕洛诺司琼及异丙嗪,对照组仅首日给予地塞米松5 mg1次,试验组给予地塞米松5 mg连续4日,观察两组患者急性期及延迟期呕吐的发生情况及毒副反应.结果:对比两组患者进食情况及呕吐情况发现,试验组较对照组呕吐得到明显控制(P＜0.05),毒副反应在可接受程度以内.结论:对于乳腺癌术后EC方案化疗的患者,帕洛诺司琼联合多日低剂量地塞米松可有效控制化疗相关性恶心呕吐的发生,同时安全性较好,在基层医院可适当推广应用.%Objective:To investigate the difference of nausea and vomiting between several or single dose of dexamethasone plus palonosetron for chemotherapy with anthracycline-cyclophosphamide combination regimen in patients of breast cancer.Methods:Eighty breast cancer patients were enrolled.They were divided into two groups.The control group(dexamethasone 5 mg for day 1) and experimental group (dexamethasone 5 mg for days 1 ～ 4).Observed in both groups of acute and delayed vomiting occurred and side effects.Results:There were significant differences in the rates of effective control between two groups as follows.The vomiting was significantly controlled in the experimental group compared with the control group(P ＜ 0.05), and the side effect was within the acceptable level.Conclusion:The results suggest that,in patients of breast cancer with low dose anthracycline-cyclophosphamide can effectively control the occarence of chemotherapy-related nausea and vomiting, and the safety is better in the primary hospital can be appropriate to promoste this therapy.